newsfilter
← Latest News
Business Wire·

Athersys Announces Favorable Preclinical Results for MultiStem® Treatment in Defense Department Radiation Countermeasure Study and Upcoming Webinar to Review Preclinical Research With MultiStem Across Multiple Indications

Athersys, Inc. (NASDAQ:ATHX) announces today results of a radiation countermeasure study conducted by the Armed Forces Radiobiology Research Institute (AFRRI), a Department of Defense research laboratory under the leadership of the Uniformed Services Un